Innoviva Inc (INVA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Innoviva Inc stock (INVA) is currently trading at $22.59. Innoviva Inc PE ratio is 13.37. Innoviva Inc PS ratio (Price-to-Sales) is 3.94. Analyst consensus price target for INVA is $36.40. WallStSmart rates INVA as Buy.
- INVA PE ratio analysis and historical PE chart
- INVA PS ratio (Price-to-Sales) history and trend
- INVA intrinsic value — DCF, Graham Number, EPV models
- INVA stock price prediction 2025 2026 2027 2028 2029 2030
- INVA fair value vs current price
- INVA insider transactions and insider buying
- Is INVA undervalued or overvalued?
- Innoviva Inc financial analysis — revenue, earnings, cash flow
- INVA Piotroski F-Score and Altman Z-Score
- INVA analyst price target and Smart Rating
Innoviva Inc
📊 No data available
Try selecting a different time range
INVA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Innoviva Inc (INVA)
INVA trades at a significant discount to its Graham intrinsic value of $77.69, offering a 71% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Innoviva Inc (INVA) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, operating margin, price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
Innoviva Inc (INVA) Key Strengths (8)
Growing significantly faster than its price suggests
Keeps $32 of every $100 in revenue after operating costs
Earnings per share surging 5479.00% year-over-year
Keeps $33 of every $100 in revenue as net profit
103.34% of shares held by major funds and institutions
Trading at 1.37x book value, attractively priced
Strong revenue growth at 20.40% annually
Solid profitability: $15 profit per $100 equity
Supporting Valuation Data
Innoviva Inc (INVA) Areas to Watch (2)
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 3.94x sales
Innoviva Inc (INVA) Detailed Analysis Report
Overall Assessment
This company scores 84/100 in our Smart Analysis, earning a A- grade. Out of 10 metrics analyzed, 8 register as strengths (avg 9.1/10) while 2 fall into concern territory (avg 5.5/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, Operating Margin, EPS Growth. Valuation metrics including PEG Ratio (0.32), Price/Book (1.37) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 15.20%, Operating Margin at 32.10%, Profit Margin at 32.80%. Growth metrics are encouraging with Revenue Growth at 20.40%, EPS Growth at 5479.00%.
The Bear Case
The primary concerns are Market Cap, Price/Sales. Some valuation metrics including Price/Sales (3.94) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 15.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 20.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of PEG Ratio and Operating Margin makes a compelling case at current levels. The key risk is Market Cap, but the overall fundamental picture is positive with a clear path to maintaining or improving the current A- grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
INVA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
INVA's Price-to-Sales ratio of 3.94x trades at a deep discount to its historical average of 61.16x (23th percentile). The current valuation is 99% below its historical high of 581.43x set in Feb 2014, and 78% above its historical low of 2.22x in Sep 2022.
WallStSmart Analysis Synopsis
Data-driven financial summary for Innoviva Inc (INVA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Innoviva Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 389M with 20% growth year-over-year. Profit margins are strong at 32.8%, reflecting pricing power and operational efficiency.
Key Findings
Profit margin of 32.8% and operating margin of 32.1% demonstrate strong pricing power and operational efficiency.
Generating 53M in free cash flow and 55M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Growth sustainability: can Innoviva Inc maintain 20%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Innoviva Inc.
Bottom Line
Innoviva Inc offers an attractive blend of growth (20% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Innoviva Inc(INVA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.